Shoulder Innovations, Inc., a commercial-stage medical advancement company operating on transforming the shoulder surgical care market, announced the full commercial launch of the InSet™ 70 Humeral Stem ("InSet™ 70").
The introduction of the InSet™ 70 represents an expansion of the company's I-Series humeral stem product line, which was first launched with the InSet™ 95 humeral stem in 2024.
The InSet™ 70 is indicated for both anatomic as well as reverse shoulder arthroplasty, addressing a wide range of clinical conditions. It is suitable for non-inflammatory degenerative joint diseases such as osteoarthritis and avascular necrosis, as well as for rheumatoid and traumatic arthritis.
It is used for correcting functional deformities. In reverse shoulder procedures, the InSet™ 70 is further indicated for irreparable rotator cuff tears, with or without arthritis, and for the revision of other devices when sufficient bone stock remains.
Executive Statement
According to Rob Ball, CEO of Shoulder Innovations, the InSet™ 70 complements their broad portfolio of advanced shoulder implant solutions, and they are excited to bring it to market across the United States ahead of schedule. SI has a strong history of innovation, and the InSet™ 70 is another example of new technology designed to enhance the quality of care for patients and provide meaningful value to the surgeons who care for them. They look forward to seeing improved patient outcomes and long-term function with this implant.
According to Galen Kam, MD., featuring the same excellent initial fixation and simple workflow as the longer InSet™ 95, the InSet™ 70 offers the added benefit of bone-sparing utility, making it a compelling offering in the shoulder care space. Essentially, this product affords all the advantages of a larger stem in a smaller, bone-preserving form factor.
